New Analyses Strengthen Efficacy | 化學工廠資訊網
2022年9月23日—Zuranoloneisaneuroactivesteroid(NAS)GABA-Areceptorpositiveallostericmodulator(PAM).Themedicationactsasamajorpartofthe ...
Eleven new analyses on zuranolone, an investigational, oral, once-daily, 14-day treatment in clinical development for adult patients with major depressive disorder (MDD) and postpartum depression, indicate the potential of the medication to improve the symptoms of depression. These data were presented at the 2022 Psych Congress in New Orleans,.
Zuranolone is a neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM). The medication acts as a major part of the inhibiting signaling pathway of the brain and central nervous system, and contributes to regulating brain function.
The ongoing open-label, longitudinal SHORELINE study in patients with MDD (30 mg cohort, 50 mg cohort) found the median time to the first repeat treatment course for patients who responded to the initial 14-day treatment course was 135 days for the completed 30 m...
Effect of Zuranolone vs Placebo in Postpartum Depression | 化學工廠資訊網
New Analyses Strengthen Efficacy | 化學工廠資訊網
Phase 3 SKYLARK Study of Zuranolone in Postpartum ... | 化學工廠資訊網
Sage Therapeutics and Biogen Announce that the Phase 3 ... | 化學工廠資訊網
Zuranolone - SAGE Therapeutics | 化學工廠資訊網
Zuranolone | 化學工廠資訊網
Zuranolone shows promise as episodic treatment for depression | 化學工廠資訊網
【新北市】瑞台生醫科技股份有限公司
新北市化工廠有哪些?本篇為大家整理位於新莊區化成路540號之1七樓之2的「瑞台生醫科技股份有限公司」相關資訊,用列表的方...